Marksans Pharma
Ticker >

Marksans Pharma share price

Marksans Pharma Ltd.

NSE: MARKSANS BSE: 524404 SECTOR: Pharmaceuticals & Drugs  205k   1k   254

174.40
+3.80 (2.23%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 178.75

Today's Low

₹ 165.5

52 Week High

₹ 185.4

52 Week Low

₹ 70.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 7903.18 Cr.

Enterprise Value

₹ 7462.91 Cr.

No. of Shares

45.32 Cr.

P/E

66.65

P/B

6.65

Face Value

₹ 1

Div. Yield

0.29 %

Book Value (TTM)

₹  26.24

CASH

₹ 440.26 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

43.85 %

EPS (TTM)

₹  2.62

Sales Growth

-0.47%

ROE

11.41 %

ROCE

14.27%

Profit Growth

-1.08 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Marksans Pharma Ltd.

RelonChem Time-Caps labs Bell's Healthcare NOVA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.47%
3 Year14.77%
5 Year17.33%

Profit Growth

1 Year-1.08%
3 Year39.49%
5 Year52.61%

ROE%

1 Year11.41%
3 Year15.11%
5 Year12.56%

ROCE %

1 Year14.27%
3 Year19.21%
5 Year16.2%

Debt/Equity

0

Price to Cash Flow

152.79

Interest Cover Ratio

37.5444229172433

CFO/PAT (5 Yr. Avg.)

0.884270606517752

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 43.85 0
Dec 2023 43.85 0
Sep 2023 43.85 0
Jun 2023 43.85 0
Mar 2023 43.85 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 39.486216489447% for the Past 3 years.
  • The company has significantly decreased its debt by 5 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 37.5444229172433.
  • Company has a healthy liquidity position with current ratio of 3.89418650505386.

 Limitations

  • The company has shown a poor revenue growth of 14.768733142436% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 41.196.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 172.75 153.05 182.04 204.67 241.36
Total Expenditure 148.93 130.34 155.28 167.37 199.39
Operating Profit 23.82 22.71 26.76 37.3 41.98
Other Income 15.71 4.3 32.62 15.93 1.33
Interest 0.85 0.66 0.26 0.23 0.27
Depreciation 4.18 3.51 4.72 8.5 8.43
Exceptional Items 0 0 0 0 0
Profit Before Tax 34.5 22.85 54.4 44.5 34.6
Tax 8.88 5.04 10.2 13.21 9.31
Profit After Tax 25.62 17.81 44.19 31.29 25.29
Adjusted EPS (Rs) 0.64 0.39 0.98 0.69 0.56

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 424.16 433.42 599.55 658.29 655.2
Total Expenditure 360.83 361.93 485.84 544.57 563.3
Operating Profit 63.33 71.49 113.71 113.72 91.9
Other Income 7.93 0.17 31.16 42.25 60.48
Interest 6.56 7.29 5.35 3.8 3.61
Depreciation 8.69 11.64 15.19 17.66 16.74
Exceptional Items 0 0 0 0 0
Profit Before Tax 56.01 52.73 124.33 134.51 132.04
Tax 12.39 14.82 25.95 30.52 29.17
Net Profit 43.62 37.9 98.38 103.99 102.87
Adjusted EPS (Rs.) 1.07 0.93 2.4 2.54 2.27

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 40.93 40.93 40.93 40.93 45.32
Total Reserves 429.64 464.69 558.79 743.74 1066.01
Borrowings 0 0 0 0 0
Other N/C liabilities 18.39 24.79 23.94 14.41 26.48
Current liabilities 135.92 79.73 137.26 190.39 240.91
Total Liabilities 624.88 610.14 760.91 989.47 1378.71
Assets
Net Block 102.61 115.18 129.09 135.51 143.94
Capital WIP 0 0 0 0 3.91
Intangible WIP 0 0 0 0 0
Investments 236.07 236.07 236.07 236.07 265.75
Loans & Advances 1.29 4.47 4.16 4.16 26.98
Other N/C Assets 0 0 0 0 0
Current Assets 284.9 254.41 391.6 613.73 938.13
Total Assets 624.88 610.14 760.91 989.47 1378.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 56.01 52.73 124.33 134.51 132.04
Adjustment 11.57 19.17 -8.82 -7.93 10.91
Changes in Assets & Liabilities -34.91 46.17 11.62 -38.77 -59.6
Tax Paid -12.86 -10.49 -20.21 -31.83 -31.62
Operating Cash Flow 19.81 107.58 106.92 55.97 51.73
Investing Cash Flow -20.2 -24.15 8.87 -128.06 -194.62
Financing Cash Flow 0.96 -81.87 -13.53 70.86 210.02
Net Cash Flow 0.56 1.55 102.26 -1.23 67.12

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 43.85 43.85 43.85 43.85 43.85
mark saldanha 43.80 43.80 43.80 43.80 43.80
sandra saldanha 0.05 0.05 0.05 0.05 0.05
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 56.15 56.15 56.15 56.15 56.15
investor education and pr... 0.14 0.14 0.14 - 0.15
orbimed asia iv mauritius... 10.88 10.88 10.88 10.88 10.88
quant mutual fund - quant... - 2.65 2.66 2.79 2.79
investor education and pr... - - - 0.15 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Marksans Pharma informs about press release18 Apr 2024, 11:22AM Marksans Pharma informs about details of loss of certificate 8 Apr 2024, 5:13PM Marksans Pharma informs about loss of share certificate3 Apr 2024, 3:31PM Marksans Pharma - Quaterly Results13 Feb 2024, 2:51PM Marksans Pharma - Quaterly Results13 Feb 2024, 2:51PM Marksans Pharma - Quaterly Results13 Feb 2024, 2:51PM Marksans Pharma informs about compliance certificate8 Jan 2024, 3:57PM Marksans Pharma informs about issuance of duplicate share certificate2 Jan 2024, 11:03AM Marksans Pharma informs about issuance of duplicate share certificates22 Dec 2023, 2:25PM Marksans Pharma - Quaterly Results9 Nov 2023, 1:29PM Marksans Pharma - Quaterly Results9 Nov 2023, 1:29PM Marksans Pharma’s arm receives Marketing Authorisation for product Cyanocobalamin 6 Nov 2023, 2:41PM Marksans Pharma informs about press release 6 Nov 2023, 1:14PM Marksans Pharma informs about press release3 Nov 2023, 1:05PM Marksans Pharma’s arm gets EIR from USFDA3 Nov 2023, 11:27AM Marksans Pharma informs about press release 1 Nov 2023, 4:59PM German health authorities inspect Marksans Pharma’s manufacturing facility in Goa1 Nov 2023, 12:29PM Marksans Pharma informs about credit rating12 Oct 2023, 3:10PM Marksans Pharma informs about compliances-certificate11 Oct 2023, 5:00PM Marksans Pharma informs about issuance of duplicate share certificate 4 Oct 2023, 12:57PM Marksans Pharma informs about trading window closure29 Sep 2023, 12:57PM Marksans Pharma informs about issuance of duplicate share certificate31 Aug 2023, 12:33PM Piramal Enterprises gets nod to raise up to Rs 3000 crore through NCDs23 Aug 2023, 11:50AM Marksans Pharma informs about disclosure22 Aug 2023, 5:12PM Marksans Pharma gets USFDA’s final approval for Guaifenesin Extended-Release Tablets22 Aug 2023, 2:59PM Marksans Pharma informs about disclosure 22 Aug 2023, 2:28PM Marksans Pharma informs about issuance of duplicate share certificate18 Aug 2023, 12:03PM Marksans Pharma informs about audio recording of call 17 Aug 2023, 10:51AM Marksans Pharma - Quaterly Results11 Aug 2023, 6:30PM Marksans Pharma - Quaterly Results11 Aug 2023, 6:30PM Marksans Pharma informs about press release 9 Aug 2023, 5:20PM Marksans Pharma submits BRSR 8 Aug 2023, 2:35PM Marksans Pharma informs about press release7 Aug 2023, 2:53PM USFDA completes PADE inspection at Marksans Pharma’s Goa facility7 Aug 2023, 2:16PM Marksans Pharma gets USFDA’s final approval for Acetaminophen and Ibuprofen Tablets12 Jul 2023, 11:57AM Marksans Pharma informs about earnings call transcript7 Jun 2023, 4:36PM Marksans Pharma informs about loss of share certificate 6 Jun 2023, 4:18PM Marksans Pharma - Quaterly Results30 May 2023, 1:50PM Marksans Pharma - Quaterly Results30 May 2023, 1:50PM Marksans Pharma - Quaterly Results30 May 2023, 1:50PM Marksans Pharma informs about compliance certificate19 Apr 2023, 5:11PM Marksans Pharma completes acquisition of manufacturing site from Tevapharm India 19 Apr 2023, 12:59PM Marksans Pharma informs about details of loss of certificate14 Apr 2023, 11:32AM Marksans Pharma informs about disclosure16 Mar 2023, 12:44PM Marksans Pharma gets USFDA’s final approval for Famotidine Tablets10 Mar 2023, 12:21PM Marksans Pharma informs about press release 10 Mar 2023, 12:14PM Marksans Pharma informs about loss of share certificate9 Mar 2023, 4:25PM Marksans Pharma informs about conference call21 Feb 2023, 4:25PM Marksans Pharma - Quaterly Results13 Feb 2023, 1:40PM Marksans Pharma - Quaterly Results13 Feb 2023, 1:40PM

Marksans Pharma Stock Price Analysis and Quick Research Report. Is Marksans Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Marksans Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Marksans Pharma cash from the operating activity was Rs 51.725 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Marksans Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Marksans Pharma , the EPS growth was -10.651027316382 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Marksans Pharma has OPM of 14.0266237690856 % which is a bad sign for profitability.
     
  • ROE: Marksans Pharma have a average ROE of 11.4112088675208 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Marksans Pharma is Rs 174.3. One can use valuation calculators of ticker to know if Marksans Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Marksans Pharma

Marksans Pharma  Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Marksans Pharma Ltd. is a leading Indian pharmaceutical company with a global footprint. The company specializes in developing and manufacturing high-quality generic and branded pharmaceuticals, including active pharmaceutical ingredients (APIs), solid oral dosage forms, liquid dosage forms, and sterile dosage forms. The company is headquartered in Mumbai, India, and has operations in more than 60 countries worldwide.

Marksans Pharma Ltd. Share Price

The share price of Marksans Pharma Ltd. is an important metric for investors to track. The price of a share reflects the market's perception of the company's prospects, and can be influenced by a wide range of factors, including economic conditions, company-specific news, and industry trends. Investors can monitor the share price of Marksans Pharma Ltd. on our website, where we offer real-time quotes and charting tools.

Marksans Pharma Ltd. Balance Sheet

The balance sheet of Marksans Pharma Ltd. provides investors with a snapshot of the company's financial health. The balance sheet shows the company's assets, liabilities, and equity at a particular point in time, and can be used to assess the company's ability to meet its obligations and fund its growth. On our website, investors can access the balance sheet of Marksans Pharma Ltd. and use our pre-built screening tools and premium fair value calculation tools, including the DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Marksans Pharma Ltd. Annual Report

The annual report of Marksans Pharma Ltd. is an important source of information for investors. The report provides details on the company's operations, financial performance, and strategy, and can be used to assess the company's prospects for growth and profitability. Investors can download the annual report of Marksans Pharma Ltd. from our website, along with other key documents such as concall transcripts, investor presentations, credit ratings, and research reports.

Marksans Pharma Ltd. Dividend

Marksans Pharma Ltd. has a track record of paying dividends to its shareholders. Dividends are a portion of the company's profits that are paid out to shareholders as a reward for their investment. Investors can track the dividends paid by Marksans Pharma Ltd. on our website, along with other key financial metrics such as earnings per share and return on equity.

Marksans Pharma Ltd. Quarterly Result

The quarterly results of Marksans Pharma Ltd. provide investors with an update on the company's financial performance over a three-month period. These results can be used to track the company's progress towards achieving its financial targets and to identify trends in its business operations. On our website, investors can access the quarterly results of Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's financial health and prospects for growth.

Marksans Pharma Ltd. Stock Price

The stock price of Marksans Pharma Ltd. is determined by the supply and demand for the company's shares on the stock market. Investors can track the stock price of Marksans Pharma Ltd. on our website, using our real-time quotes and charting tools. The stock price is an important indicator of the market's perception of the company's prospects, and can be influenced by a wide range of factors, including economic conditions, company-specific news, and industry trends.

Marksans Pharma Ltd. Price Chart

The price chart of Marksans Pharma Ltd. provides investors with a visual representation of the company's stock price over time. This chart can be used to identify trends in the stock price and to assess the company's performance relative to its peers and the broader stock market. On our website, investors can access the price chart of Marksans Pharma Ltd. and use our charting tools to customize the display and analyze the data.

Marksans Pharma Ltd. News

Keeping up with the latest news and events related to Marksans Pharma Ltd. is an important part of stock analysis. Investors can access the latest news and press releases related to Marksans Pharma Ltd. on our website, as well as other sources of news and commentary from around the web. Our news aggregator pulls together news headlines, articles, and blogs related to the company, making it easy for investors to stay up-to-date with the latest developments.

Marksans Pharma Ltd. Concall Transcripts

Concall transcripts provide investors with a detailed record of the company's conference calls with analysts and investors. These transcripts can provide insight into the company's strategy, operations, and prospects, and can be used to identify trends and risks that may impact the company's stock price. On our website, investors can access concall transcripts for Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's performance and prospects.

Marksans Pharma Ltd. Investor Presentations

Investor presentations are an important source of information for investors, providing an overview of the company's strategy, operations, and financial performance. On our website, investors can access investor presentations for Marksans Pharma Ltd. and use our premium fair value calculation tools to assess the company's prospects for growth and profitability.

Marksans Pharma Ltd. Promoters

The promoters of Marksans Pharma Ltd. are a group of individuals or entities who hold a significant stake in the company and have a vested interest in its success. Understanding the motives and actions of the promoters can provide insight into the company's prospects and risks. On our website, investors can access information about the promoters of Marksans Pharma Ltd. and use our screening tools and premium fair value calculation tools to analyze their impact on the company.

Marksans Pharma Ltd. Shareholders

The shareholders of Marksans Pharma Ltd. play an important role in the company's governance and decision-making process. Understanding the composition and actions of the shareholder base can provide insight into the company's prospects and risks. On our website, investors can access information about the shareholders of Marksans Pharma Ltd. and use our screening tools and premium fair value calculation tools to analyze their impact on the company.

Overall, Marksans Pharma Ltd. is a leading Indian pharmaceutical company with a global footprint. Investors seeking to analyze the company's stock should consider a wide range of factors, including its financial performance, strategy, industry trends, and market conditions. By accessing key information and analysis on our website, investors can stay ahead of the curve and make informed decisions about their investments.

Read More
X